We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
3. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
4. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
5. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
6. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
7. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
8. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
9. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
17. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
18. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
19. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
20. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
22. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
23. Hemophilia A
- Dr. Snejana Krassova
-
26. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
27. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
28. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
29. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
30. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
32. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
33. Rac-enhanced CAR immunotherapy: RaceCAR
- Prof. Denise Montell
-
34. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 1
- Prof. Kevin Harrington
-
35. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 2
- Prof. Kevin Harrington
-
36. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
37. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
38. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
39. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
40. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
41. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
42. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
43. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
45. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
46. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
47. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
48. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
49. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
50. Cow’s milk allergy: the future
- Dr. Carina Venter
-
51. Cow's milk allergy: management
- Dr. Carina Venter
-
52. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
53. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
54. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
55. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
56. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
57. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
58. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
59. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
60. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
61. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
63. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
64. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
65. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
66. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
67. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
68. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
69. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
-
70. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
71. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
72. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
73. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
74. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
75. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
76. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
77. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
78. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
79. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
80. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
81. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
82. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
83. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
84. AI and big data in drug discovery
- Mr. Ed Addison
-
85. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
86. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
87. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
88. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
89. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
90. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
91. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
92. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
93. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
94. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
95. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
96. New drugs for asthma
- Prof. Peter Barnes
-
97. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
98. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
Printable Handouts
Navigable Slide Index
- Introduction
- Human transcription and processing
- Types of non-coding RNAs
- Part I - MicroRNAs
- miRNA biogenesis
- miRNA biogenesis and cancer
- miRNAs are implicated in several cancers
- Application of miRNAs in cancer
- Role of miRNAs in cancer: as biomarkers
- miRNAs as diagnostic markers
- miRNAs as prognostic markers
- miRNAs as predictive markers
- MiRNA polymorphisms (miR-SNPs) in cancer
- miR-SNPs in cancer - clinical trials
- Role of miRNAs in cancer: as therapeutic agents
- Strategies to inhibit Onco-miRs - Anti miRs
- Antisense oligonucleotides
- Strategies to inhibit Onco-miRs - Small molecules
- Strategies to inhibit Onco-miRs - miRNA sponges
- Strategies to restore TS-miRs - miRNA mimics
- Strategies to restore TS-miRs
- Delivery system for miRNA therapeutics - GalNac
- Delivery system for miRNA therapeutics - EDV
- Clinical development of miRNA therapeutics
- Part II - long non-coding RNAs (lncRNAs)
- The diversity of lncRNAs
- LncRNAs are implicated in several cancers
- LncRNAs - cancer-associated pathways
- Application of lncRNAs in cancer
- Role of lncRNAs in cancer: as biomarkers
- Role of lncRNAs in cancer: gene biomarker lists
- LncRNAs as risk markers
- LncRNAs as risk markers - PACT1 enhancer
- LncRNAs as risk markers - CCAT2
- LncRNAs as diagnostic & prognostic markers
- LncRNAs as diagnostic markers
- LncRNAs as prognostic markers - NKILA
- LncRNAs as prognostic markers - A12-LncRNA
- LncRNAs as predictive markers - CCAT1
- LncRNAs as predictive markers - LINK-A
- LncRNAs currently in clinical trials as biomarkers
- Role of lncRNAs in cancer: as therapeutic agents
- Challenges of targeting lncRNAs
- Take home messages
Topics Covered
- Types of non-coding RNAs
- Role of microRNAs and long non-coding RNAs in cancers
- Recent advances in strategies to utilize miRNAs and lncRNAs as biomarkers in cancer
- miRNAs and lncRNAs are currently in clinical development as diagnostic, prognostic and predictive biomarkers for cancer
- Recent advances in strategies to utilize miRNAs and lncRNAs as therapeutic targets in cancer
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Calin, G. and Shah, M. (2018, February 28). Recent advances in the field of non-coding RNAs in cancer [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved February 14, 2025, from https://doi.org/10.69645/JOJJ9323.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. George Calin has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Dr. Maitri Shah has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Transcript
Please wait while the transcript is being prepared...
0:00
Hello everyone, I am Maitri Shah,
I'm a Postdoctoral Fellow in Dr. George Calin's lab
at MD Anderson Cancer Center in Houston, Texas.
Today, I'll be talking about
the recent advances in the field of non-coding RNAs in cancer,
particularly those in the last two years
that have influenced research and clinical practice.
0:21
Integrated use of advanced genome analysis platforms in recent years by consortia
such as the Human Genome Project and the Encyclopedia of DNA Elements or ENCODE Project,
have revealed that the transcription and processing of
the human genome yields a diverse catalog of non-coding RNAs.
The protein-coding genes occupy less than two percent of the human genome.
These protein-coding genes account for approximately one-third of all annotated genes;
whereas, long and small non-coding RNAs genes,
together account for 40 percent of the genes.
Considering their ubiquitous presence and diversity,
these non-coding RNAs have attracted a lot of attention in the past decade and
extensive research has been performed to understand
their role in normal cellular physiological processes,
as well as in human diseases.
1:15
Non-coding RNAs are arbitrarily classified into
short and long non-coding RNA based on the transcript size.
Small non-coding RNAs are shorter than 200 nucleotides.
This category includes microRNAs,
endogenous small interfering RNAs or siRNAs,
small nucleolar RNAs or snoRNAs,
and PIWI-interacting RNAs or piRNAs.
Long non-coding RNAs are longer than 200 nucleotides
and include long intergenic non-coding RNAs or lincRNAs,
natural antisense transcripts or NATs,
transcribed ultra-conserved regions or T-UCRs,
long enhancer non-coding RNAs,
non-coding repeat sequences, and pseudogenes.
First, I would like to talk about microRNAs,